These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14968593)

  • 1. [New therapeutic agents for chronic hepatitis C].
    Hiramatsu N; Hayashi N
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):170-7. PubMed ID: 14968593
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress on the treatment of hepatitis C.
    Nierengarten MB
    Lancet Infect Dis; 2003 Dec; 3(12):748. PubMed ID: 14664249
    [No Abstract]   [Full Text] [Related]  

  • 3. [Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C].
    Izumi N; Kurosaki M; Suzuki S; Tamaki N
    Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2108-11. PubMed ID: 23221060
    [No Abstract]   [Full Text] [Related]  

  • 4. [Healing of chronic hepatitis C following 12 weeks of therapy with peginterferon-alpha and ribavirin].
    Barreales M; Castellano G; Fernández I; Muñoz R; Manzano M; Solís Herruzo JA
    Rev Esp Enferm Dig; 2007 Dec; 99(12):738-40. PubMed ID: 18290706
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 6. Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
    Hrachovec J; Patel P
    Gastroenterology; 2003 Jun; 124(7):2003-4; author reply 2004-5. PubMed ID: 12812198
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anti-viral therapy of type C chronic hepatitis. 3. New development in anti-viral therapy of type C chronic hepatitis--Peg-IFN/ribavirin combination therapy and a new anti-viral treatment].
    Hiramatsu N
    Nihon Naika Gakkai Zasshi; 2008 Jan; 97(1):75-81. PubMed ID: 18360974
    [No Abstract]   [Full Text] [Related]  

  • 8. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
    Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment for chronic hepatitis C.
    Bacon BR
    Curr Gastroenterol Rep; 2003 Feb; 5(1):1-2. PubMed ID: 12530942
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
    Sagir A; Wettstein M; Heintges T; Häussinger D
    Dig Dis Sci; 2002 Mar; 47(3):562-3. PubMed ID: 11911342
    [No Abstract]   [Full Text] [Related]  

  • 11. The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C.
    Dai CY; Huang CF; Chuang WL; Huang JF; Yu ML
    Am J Gastroenterol; 2009 Sep; 104(9):2358-9. PubMed ID: 19727098
    [No Abstract]   [Full Text] [Related]  

  • 12. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
    Asahina Y; Izumi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
    [No Abstract]   [Full Text] [Related]  

  • 13. [Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis].
    Klinker H
    MMW Fortschr Med; 2003 Oct; 145(41):39-40. PubMed ID: 14655480
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.
    Kim DY
    Gut Liver; 2014 Jul; 8(4):335-6. PubMed ID: 25071896
    [No Abstract]   [Full Text] [Related]  

  • 15. Do differences in pegylation of interferon alfa matter?
    Zeuzem S
    Gastroenterology; 2010 Jan; 138(1):34-6. PubMed ID: 19932662
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversal of cirrhosis: evidence-based medicine?
    Desmet VJ; Roskams T
    Gastroenterology; 2003 Aug; 125(2):629-30; author reply 630-31. PubMed ID: 12891578
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.
    Lo Nigro L; La Spina M; Mirabile E; Pisana P; Schilirò G; Guardo P
    Pediatr Blood Cancer; 2004 Aug; 43(2):185. PubMed ID: 15236293
    [No Abstract]   [Full Text] [Related]  

  • 18. Side effects of therapy for chronic hepatitis C.
    Russo MW; Fried MW
    Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
    [No Abstract]   [Full Text] [Related]  

  • 19. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Nishiofuku M; Tsujimoto T; Matsumura Y; Toyohara M; Yoshiji H; Yamao J; Fukui H; Yoshikawa M
    Intern Med; 2006; 45(7):483-4. PubMed ID: 16679707
    [No Abstract]   [Full Text] [Related]  

  • 20. [Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C].
    Han KH; Yoon YH
    Korean J Hepatol; 2004 Jun; 10(2):81-7. PubMed ID: 15218341
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.